Melanoma is a malignant skin tumor characterized by a propensity for early metastasis and high mortality rates. Immune checkpoint inhibitors have significantly improved the prognosis for melanoma patients, however, some individuals remain unresponsive to immunotherapy, primarily due to the immunosuppressive characteristics of the tumor microenvironment. This review summarizes recent research on the melanoma tumor microenvironment and analyzes how dynamic changes in its components influence melanoma development and the efficacy of immunotherapy. Additionally, it outlines immunotherapy strategies focused on immune checkpoint inhibitors, examines their mechanisms of action and limitations, and further investigates the effects of combining immune checkpoint inhibitors with various therapeutic modalities, including radiotherapy, chemotherapy, and targeted therapies. This study aims to provide new insights into the melanoma tumor microenvironment and the advancement of personalized precision immunotherapy.

Melanoma is a malignant skin tumor characterized by a propensity for early metastasis and high mortality rates. Immune checkpoint inhibitors have significantly improved the prognosis for melanoma patients, however, some individuals remain unresponsive to immunotherapy, primarily due to the immunosuppressive characteristics of the tumor microenvironment. This review summarizes recent research on the melanoma tumor microenvironment and analyzes how dynamic changes in its components influence melanoma development and the efficacy of immunotherapy. Additionally, it outlines immunotherapy strategies focused on immune checkpoint inhibitors, examines their mechanisms of action and limitations, and further investigates the effects of combining immune checkpoint inhibitors with various therapeutic modalities, including radiotherapy, chemotherapy, and targeted therapies. This study aims to provide new insights into the melanoma tumor microenvironment and the advancement of personalized precision immunotherapy.